Cisplatin chemoprotection and rescue: Pharmacologic modulation of toxicity

David R. Gandara, Edith A. Perez, Valerie Wiebe, Michael W. De Gregorio

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Although cisplatin is one of the most important antitumor agents yet developed, associated toxicities continue to limit its potential usefulness. Depending on the cisplatin dose and method of administration, limiting toxicities may include nephropathy, ototoxicity, peripheral neuropathy, or even myelosuppression. Recent therapeutic strategies such as hypertonic saline have proven successful in reducing the incidence of renal insufficiency, thus allowing cisplatin dose escalation to the level of 200 mg/m2 per 28-day cycle. Unfortunately, ototoxicity and a cumulative dose-related peripheral neuropathy have recently emerged as additional dose-limiting toxicities. One method of optimizing the therapeutic index of cisplatin is the concurrent administration of chemoprotective or rescue therapy. Ideally, an effective rescue agent would selectively reduce cisplatin-related side effects without reversing its antitumor activity. Three chemoprotective agents currently undergoing evaluation-WR-2721 (ethiofos), DDTC (diethyldithiocarbamate), and ORG-2766-have demonstrated preclinical efficacy. Clinical trials now in progress suggest that each agent may offer unique advantages, but many questions remain regarding the optimal use of these agents.

Original languageEnglish (US)
Pages (from-to)49-55
Number of pages7
JournalSeminars in Oncology
Volume18
Issue number1 SUPPL. 3
StatePublished - 1991
Externally publishedYes

Fingerprint

Cisplatin
Amifostine
Peripheral Nervous System Diseases
Ditiocarb
Antineoplastic Agents
Renal Insufficiency
Therapeutics
Clinical Trials
Incidence

ASJC Scopus subject areas

  • Oncology

Cite this

Gandara, D. R., Perez, E. A., Wiebe, V., & De Gregorio, M. W. (1991). Cisplatin chemoprotection and rescue: Pharmacologic modulation of toxicity. Seminars in Oncology, 18(1 SUPPL. 3), 49-55.

Cisplatin chemoprotection and rescue : Pharmacologic modulation of toxicity. / Gandara, David R.; Perez, Edith A.; Wiebe, Valerie; De Gregorio, Michael W.

In: Seminars in Oncology, Vol. 18, No. 1 SUPPL. 3, 1991, p. 49-55.

Research output: Contribution to journalArticle

Gandara, DR, Perez, EA, Wiebe, V & De Gregorio, MW 1991, 'Cisplatin chemoprotection and rescue: Pharmacologic modulation of toxicity', Seminars in Oncology, vol. 18, no. 1 SUPPL. 3, pp. 49-55.
Gandara DR, Perez EA, Wiebe V, De Gregorio MW. Cisplatin chemoprotection and rescue: Pharmacologic modulation of toxicity. Seminars in Oncology. 1991;18(1 SUPPL. 3):49-55.
Gandara, David R. ; Perez, Edith A. ; Wiebe, Valerie ; De Gregorio, Michael W. / Cisplatin chemoprotection and rescue : Pharmacologic modulation of toxicity. In: Seminars in Oncology. 1991 ; Vol. 18, No. 1 SUPPL. 3. pp. 49-55.
@article{14835156e690425c9cd47a1271681f2b,
title = "Cisplatin chemoprotection and rescue: Pharmacologic modulation of toxicity",
abstract = "Although cisplatin is one of the most important antitumor agents yet developed, associated toxicities continue to limit its potential usefulness. Depending on the cisplatin dose and method of administration, limiting toxicities may include nephropathy, ototoxicity, peripheral neuropathy, or even myelosuppression. Recent therapeutic strategies such as hypertonic saline have proven successful in reducing the incidence of renal insufficiency, thus allowing cisplatin dose escalation to the level of 200 mg/m2 per 28-day cycle. Unfortunately, ototoxicity and a cumulative dose-related peripheral neuropathy have recently emerged as additional dose-limiting toxicities. One method of optimizing the therapeutic index of cisplatin is the concurrent administration of chemoprotective or rescue therapy. Ideally, an effective rescue agent would selectively reduce cisplatin-related side effects without reversing its antitumor activity. Three chemoprotective agents currently undergoing evaluation-WR-2721 (ethiofos), DDTC (diethyldithiocarbamate), and ORG-2766-have demonstrated preclinical efficacy. Clinical trials now in progress suggest that each agent may offer unique advantages, but many questions remain regarding the optimal use of these agents.",
author = "Gandara, {David R.} and Perez, {Edith A.} and Valerie Wiebe and {De Gregorio}, {Michael W.}",
year = "1991",
language = "English (US)",
volume = "18",
pages = "49--55",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 3",

}

TY - JOUR

T1 - Cisplatin chemoprotection and rescue

T2 - Pharmacologic modulation of toxicity

AU - Gandara, David R.

AU - Perez, Edith A.

AU - Wiebe, Valerie

AU - De Gregorio, Michael W.

PY - 1991

Y1 - 1991

N2 - Although cisplatin is one of the most important antitumor agents yet developed, associated toxicities continue to limit its potential usefulness. Depending on the cisplatin dose and method of administration, limiting toxicities may include nephropathy, ototoxicity, peripheral neuropathy, or even myelosuppression. Recent therapeutic strategies such as hypertonic saline have proven successful in reducing the incidence of renal insufficiency, thus allowing cisplatin dose escalation to the level of 200 mg/m2 per 28-day cycle. Unfortunately, ototoxicity and a cumulative dose-related peripheral neuropathy have recently emerged as additional dose-limiting toxicities. One method of optimizing the therapeutic index of cisplatin is the concurrent administration of chemoprotective or rescue therapy. Ideally, an effective rescue agent would selectively reduce cisplatin-related side effects without reversing its antitumor activity. Three chemoprotective agents currently undergoing evaluation-WR-2721 (ethiofos), DDTC (diethyldithiocarbamate), and ORG-2766-have demonstrated preclinical efficacy. Clinical trials now in progress suggest that each agent may offer unique advantages, but many questions remain regarding the optimal use of these agents.

AB - Although cisplatin is one of the most important antitumor agents yet developed, associated toxicities continue to limit its potential usefulness. Depending on the cisplatin dose and method of administration, limiting toxicities may include nephropathy, ototoxicity, peripheral neuropathy, or even myelosuppression. Recent therapeutic strategies such as hypertonic saline have proven successful in reducing the incidence of renal insufficiency, thus allowing cisplatin dose escalation to the level of 200 mg/m2 per 28-day cycle. Unfortunately, ototoxicity and a cumulative dose-related peripheral neuropathy have recently emerged as additional dose-limiting toxicities. One method of optimizing the therapeutic index of cisplatin is the concurrent administration of chemoprotective or rescue therapy. Ideally, an effective rescue agent would selectively reduce cisplatin-related side effects without reversing its antitumor activity. Three chemoprotective agents currently undergoing evaluation-WR-2721 (ethiofos), DDTC (diethyldithiocarbamate), and ORG-2766-have demonstrated preclinical efficacy. Clinical trials now in progress suggest that each agent may offer unique advantages, but many questions remain regarding the optimal use of these agents.

UR - http://www.scopus.com/inward/record.url?scp=0025857621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025857621&partnerID=8YFLogxK

M3 - Article

C2 - 1848372

AN - SCOPUS:0025857621

VL - 18

SP - 49

EP - 55

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 3

ER -